MRNA-1283: Difference between revisions

MRNA-1283
Vaccine description
Target	SARS-CoV-2
Vaccine type	mRNA
Clinical data
Routes of; administration	Intramuscular

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 08:45, 23 December 2021

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.^[1]^[2]

References

^ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.

Scholia has a profile for mRNA-1283 (Q110263526).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

[1] "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.

[2] "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.

[1]

[2]

@@ Line 42: / Line 42: @@
 }}
 {{COVID-19 pandemic sidebar}}
-'''mRNA-1283''' is a [[COVID-19 vaccine]] candidate developed by [[Moderna]].<ref>{{#invoke:Cite web| |title=A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04813796 |website=[[ClinicalTrials.gov]] |date=24 March 2021 |id=NCT04813796 |access-date=17 August 2021 }}</ref><ref>{{#invoke:Cite web| |title=Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04962893 |website=[[ClinicalTrials.gov]] |date=15 July 2021 |id=NCT04962893 |access-date=15 July 2021 }}</ref>
+'''mRNA-1283''' is a [[COVID-19 vaccine]] candidate developed by [[Moderna]].<ref>{{#invoke:Cite web| |title=A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04813796 |website=[[ClinicalTrials.gov]] |date=24 March 2021 |id=NCT04813796 |access-date=17 August 2021 }}</ref><ref>{{#invoke:Cite web| |title=A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters |url=https://clinicaltrials.gov/ct2/show/NCT05137236 |website=[[ClinicalTrials.gov]] |date=30 November 2021 |id=NCT05137236 |access-date=30 November 2021 }}</ref>
 == References ==